Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer's disease

BackgroundAlzheimer's disease (AD) is a progressive multifaceted neurodegenerative disorder for which no disease-modifying treatment exists. Neuroinflammation is central to the pathology progression, with evidence suggesting that microglia-released galectin-3 (gal3) plays a pivotal role by amplifying neuroinflammation in AD. However, the possible involvement of gal3 in the disruption of neuronal network oscillations typical of AD remains unknown.MethodsHere, we investigated the functional implications of gal3 signaling on experimentally induced gamma oscillations ex vivo (20-80 Hz) by performing electrophysiological recordings in the hippocampal CA3 area of wild-type (WT) mice and of the 5xFAD mouse model of AD. In addition, the recorded slices from WT mice under acute gal3 application were analyzed with RT-qPCR to detect expression of some neuroinflammation-related genes, and amyloid-beta (A beta) plaque load was quantified by immunostaining in the CA3 area of 6-month-old 5xFAD mice with or without Gal3 knockout (KO).ResultsGal3 application decreased gamma oscillation power and rhythmicity in an activity-dependent manner, which was accompanied by impairment of cellular dynamics in fast-spiking interneurons (FSNs) and pyramidal cells. We found that the gal3-induced disruption was mediated by the gal3 carbohydrate-recognition domain and prevented by the gal3 inhibitor TD139, which also prevented A beta 42-induced degradation of gamma oscillations. Furthermore, the 5xFAD mice lacking gal3 (5xFAD-Gal3KO) exhibited WT-like gamma network dynamics and decreased A beta plaque load.ConclusionsWe report for the first time that gal3 impairs neuronal network dynamics by spike-phase uncoupling of FSNs, inducing a network performance collapse. Moreover, our findings suggest gal3 inhibition as a potential therapeutic strategy to counteract the neuronal network instability typical of AD and other neurological disorders encompassing neuroinflammation and cognitive decline.

Automated summary

The neuroinflammation factor galectin-3 (gal3) disrupts neuronal network oscillations in Alzheimer's disease (AD). Gal3 application decreases gamma oscillation power and rhythmicity, impairing cellular dynamics and inducing a collapse in network performance. Inhibition of gal3 may be a potential therapeutic strategy for treating AD and other neuroinflammatory disorders.